基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma)):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H2 2014
◆商品コード:GMDHC5783IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月30日
◆ページ数:77
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))の概要
・基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))治療薬開発に取り組んでいる企業:企業別製品パイプライン
・基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma))治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Review, H2 2014’, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Basal Cell Carcinoma (Basal Cell Epithelioma) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Basal Cell Carcinoma (Basal Cell Epithelioma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview 8
Therapeutics Development 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) – Overview 9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) – Comparative Analysis 10
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics under Investigation by Universities/Institutes 13
Basal Cell Carcinoma (Basal Cell Epithelioma) – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Basal Cell Carcinoma (Basal Cell Epithelioma) – Products under Development by Companies 17
Basal Cell Carcinoma (Basal Cell Epithelioma) – Products under Investigation by Universities/Institutes 18
Basal Cell Carcinoma (Basal Cell Epithelioma) – Companies Involved in Therapeutics Development 19
4SC AG 19
Biofrontera AG 20
Biosceptre International Limited 21
Bristol-Myers Squibb Company 22
Genextra S.p.a. 23
InMed Pharmaceuticals Inc. 24
Mayne Pharma Group Limited 25
MediGene AG 26
Novartis AG 27
Oncovir, Inc. 28
Transgene SA 29
Basal Cell Carcinoma (Basal Cell Epithelioma) – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Combination Products 31
Assessment by Target 32
Assessment by Mechanism of Action 34
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
aminolevulinic acid hydrochloride – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
ASN-002 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
BIL-010t – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
BMS-833923 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CIGB-128 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CS-S/BCC-1 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CS-TATI-1 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
DAC-0060 – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
erismodegib – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
itraconazole – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
LEQ-506 – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Oshadi D + Oshadi R – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Poly-ICLC – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
sinecatechins – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Small Molecules to Inhibit Casein Kinase 1 for Cancer – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Basal Cell Carcinoma (Basal Cell Epithelioma) – Recent Pipeline Updates 62
Basal Cell Carcinoma (Basal Cell Epithelioma) – Dormant Projects 71
Basal Cell Carcinoma (Basal Cell Epithelioma) – Discontinued Products 72
Basal Cell Carcinoma (Basal Cell Epithelioma) – Product Development Milestones 73
Featured News & Press Releases 73
Sep 17, 2014: Novartis presents oncology research advances with new data on sonidegib at ESMO 2014 73
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma 73
Jun 01, 2014: Pivotal data for Novartis’ investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma 74
Feb 19, 2014: Novartis investigational compound LDE225 met primary endpoint in pivotal trial for patients with advanced basal cell carcinoma 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 77
Disclaimer 77

[List of Tables]
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2014 9
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H2 2014 19
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H2 2014 20
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Limited, H2 2014 21
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Company, H2 2014 22
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra S.p.a., H2 2014 23
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by InMed Pharmaceuticals Inc., H2 2014 24
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Limited, H2 2014 25
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H2 2014 26
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Novartis AG, H2 2014 27
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Oncovir, Inc., H2 2014 28
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H2 2014 29
Assessment by Monotherapy Products, H2 2014 30
Assessment by Combination Products, H2 2014 31
Number of Products by Stage and Target, H2 2014 33
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 37
Number of Products by Stage and Molecule Type, H2 2014 39
Basal Cell Carcinoma (Basal Cell Epithelioma) Therapeutics - Recent Pipeline Updates, H2 2014 62
Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H2 2014 71
Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H2 2014 72

[List of Figures]
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2014 9
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Assessment by Monotherapy Products, H2 2014 30
Number of Products by Top 10 Targets, H2 2014 32
Number of Products by Stage and Top 10 Targets, H2 2014 33
Number of Products by Top 10 Mechanism of Actions, H2 2014 34
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 35
Number of Products by Top 10 Routes of Administration, H2 2014 36
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 37
Number of Products by Top 10 Molecule Types, H2 2014 38
Number of Products by Stage and Top 10 Molecule Types, H2 2014 39

【掲載企業】

4SC AG
Biofrontera AG
Biosceptre International Limited
Bristol-Myers Squibb Company
Genextra S.p.a.
InMed Pharmaceuticals Inc.
Mayne Pharma Group Limited
MediGene AG
Novartis AG
Oncovir, Inc.
Transgene SA

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[基底細胞癌(基底細胞上皮腫)(Basal Cell Carcinoma (Basal Cell Epithelioma)):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆